Home Latest Articles
Latest Articles
  • Boran DU, Xiangjun SHI, Xueyan ZHANG, Ran WANG, Chenghong YIN, Xin FENG
    World Clinical Drug. 2024, 45(2): 153-161.
    Objective

    To operate a rapid health technology assessment for treatment of endometriosis with dienogest, providing evidence for clinical evaluation and decision-making.

    Methods

    The researches of dienogest on endometriosis were searched in Pubmed, Embase, CNKI, Wanfang and other databases. AMSTAR, OQAQ and CHEERS (2022) were used to evaluate the methodological quality of health economics, and the treatment of endometriosis with dienogest was comprehensive evaluated.

    Results

    The comprehensive evaluation results showed that dienogest had obvious advantages in preventing recurrence rate and improving pain after endometriosis surgery compared with expectant treatment, and was comparable to gonadotrophin releasing hormone analogue (GnRH-a). On safety evaluation, compared with other therapeutic drugs, dienogest had a higher risk of vaginal bleeding, and the risk of headache and weight gain also should be noted, while the risk of hot flashes, vaginal dryness and osteoporosis was relatively small. From perspective of medical insurance payment, dienogest was more cost-effective compared with GnRH-a, but had no advantage compared with combined oral contraceptives (COC).

    Conclusion

    Dienogest could be used as a long-term maintenance treatment after endometriosis surgery. However, compared with other treatments such as GnRH-a and COC, the efficacy, safety, and pharmacoeconomics of dienogest should be further explored.

  • Haiyu XU, Hao YAN, Liming LIU, Jiayu QIU, Wei CHENG
    World Clinical Drug. 2024, 45(2): 162-170.
    Objective

    To evaluate the efficacy and cost of Xihuang pill combined with chemotherapy in the treatment of breast cancer by cost-effectiveness analysis based on the meta-analysis, and to provide reference for clinical optimization of health resource allocation.

    Methods

    Xihuang Pill and chemotherapy were the treatment group, and conventional chemotherapy were the control group. According to the Cocharane system evaluation, RevMan5.4 software was used to conduct meta-analysis and count the costs of two groups. Cost-effectiveness and sensitivity analysis were performed by comparing the differences in efficacy and costs.

    Results

    A total of 7 randomized controlled trials were included in the article. According to the results of meta-analysis, the difference in the effective rate of Xihuang pill combined with chemotherapy compared with the control group was statistically significant (P<0.05), and the clinical effective rate and safety were higher and the recurrence rate was lower compared with the control group. Meanwhile, the results of cost-effectiveness analysis showed that the cost-effectiveness ratio of Xihuang pill combined with cyclophosphamide+Doxorubicin hydrochloride (Adriamycin)+fluorouracil (CAF) regimen was ¥101.07, and the cost-effectiveness ratio of Xihuang pill combined with cyclophosphamide+Epirubicin+fluorouracil (CEF) regimen was ¥64.54, both of which was lower than that of the control group. And the incremental cost effectiveness ratio values of the two scenarios were ¥59.97 and ¥48.13, respectively, which indicated that the Xihuang pill combined with CAF and CEF regimen had a greater cost-effectiveness advantage. The cost-effectiveness of Xihuang pill combined with other programs was not obvious.

    Conclusion

    Xihuang pill combined with CAF and CEF regimen is more economical in the treatment of breast cancer, and is the preferred treatment scheme.

  • Aiqiao GENG, Wenjing JIANG, Zhifang ZHANG
    World Clinical Drug. 2024, 45(2): 171-175.
    Objective

    To investigate the effects of antenatal corticosteroid (ACS) therapy on neonatal respiratory distress syndrome (NRDS) in late preterm infants.

    Methods

    Medical records of late preterm infants whose gestational age was 34 weeks≤age<37 weeks, from June 2019 to June 2022 were retrospectively analyzed. According to whether the use of ACS was standardized to promote fetal lung maturation, they were divided into normative group (n=71) and non-normative group (n=79), NRDS in normative group (n=27) and NRDS in non-normative group (n=36). The effects of ACS on the incidence of NRDS, invasive ventilation time, non-invasive ventilation time, hospital stay, hospitalization costs, the use of pulmonary surfactant (PS) and complications were analyzed.

    Results

    The gestational age of normative group was higher than that of non- normative group, and the difference was statistically significant (P<0.05). The occurrence of NRDS in the normative group was larger than that in the non- normative group (P<0.05), and the number of PS users, invasive ventilation time and hospitalization costs were decreased (P<0.05), and the incidence of intracranial hemorrhage was decreased (P<0.05).

    Conclusion

    Although the standard use of ACS can't reduce the incidence of NRDS, but it can improve the condition of children, reduce the use of PS, invasive ventilation time and hospitalization costs, reduce the incidence of intraventricular hemorrhage, and do not increase the incidence of other complications.

  • Jing LIN, Fahua SHI, Xiaofei WANG
    World Clinical Drug. 2024, 45(2): 176-180.
  • Linjun CAI, Jing LEI, Wenfei LIU, Yingying QIAN, Jiyong MA
    World Clinical Drug. 2024, 45(2): 181-186.

    Copper is involved in many life processes, and imbalance of copper homeostasis leads to cell death, a process known as copper death. Tumor cells maintained higher cellular activity and higher copper load. Copper carriers and related drugs can induce copper overload in tumor cells and lead to copper death of tumor cells. This article reviewed the relationship between copper death and cancer and the anticancer mechanism of copper carrier drugs.

  • Meiqi CHEN, Shupan FAN, Yunyun YANG, Juan WANG, Li LIU, Zhuo WANG
    World Clinical Drug. 2024, 45(2): 187-191.

    Prostate cancer (PCa) is one of the most common malignancies in men, and due to its high heterogeneity and drug resistance, general treatment cannot provide maximum benefit to patients.. The prostate development of rodents is quite different from that of human. The existing 2 dimensional model cannot reproduce the unique characteristics of PCa patients. The appearance of in vitro organoid model provides a new idea for PCa research, and bridges the gap between 2 dimensional culture and in vivo model. This paper reviewed describes some existing prostate models, including 2 dimensional cell line models, patient-derived xenotransplantation models (organoid models derived from patients, circulating tumor cell, induced pluripotent stem cells) and organoid models derived from patient-derived xenotransplantation, outlined their advantages and disadvantages in the application.

  • Baixue DONG, Yi REN, Jing YANG
    World Clinical Drug. 2024, 45(2): 192-197.

    Diabetes mellitus (DM) has always been one of the major global public health issues. Insulin has been an irreplaceable drug for controlling blood sugar in DM patients for a long time. In order to obtain better hypoglycemic effect and improve patient compliance, insulin preparations are constantly updated and iterated. This article reviewed the research progress in weekly basal insulin, oral insulin administration route and insulin compound preparation, in order to provide reference for clinical practice.

  • Jiayi XU, Yuehua BAO, Yigang TONG, Shan YE
    World Clinical Drug. 2024, 45(2): 198-203.

    Graft-versus-host disease (GVHD) is the most significant complication after allogeneic stem cell transplantation. Hormone drugs are the first choice for the treatment of GVHD, but they have limitations in clinical use. This paper reviewed the new GVHD therapeutic drugs and those under development, to provide a reference for clinical use.

  • Fengnian GUO, Yuan ZHAO, Jun HE, Weigen LU
    World Clinical Drug. 2024, 45(2): 204-208.

    Neonatal respiratory distress syndrome (NRDS) is a neonatal respiratory disease caused by insufficient secretion of pulmonary surfactant (PS) due to immature lung tissue, it can cause progressive dyspnea, respiratory failure and other lung symptoms. PS replacement therapy is widely used in clinical practice to treat NRDS. With the deepening of related studies and the continuous enrichment of clinical medication knowledge, more and more clinical optimal drug delivery routes of PS have been reported. This article reviewed the clinical application of PS in NRDS and summarized the latest research results of new PS, administration route, administration timing, administration dose, and administration device, and also discussed the possibility application of PS in other respiratory diseases, to provide the reference for improving the level of clinical application of PS.

  • Shanshan TANG, Yufan WANG
    World Clinical Drug. 2024, 45(2): 209-212.

    Insulin plays an important role in the treatment of diabetes mellitus (DM). With the prolongation of the continuous action time of insulin analogues and the decrease of the variability of the drug effect, the long-acting basic insulin came into being. In order to seek better basic insulin that is conducive to blood glucose control and improve long-term clinical outcomes, while maximizing patient compliance and treatment continuity, eliminating barriers to initial insulin therapy, and without increasing the risk of hypoglycemia, it is imperative to develop weekly basal insulin. This article focused on the two most advanced weekly basal insulin, and reviewed their molecular structure, pharmacokinetics and published clinical study data for clinical application.

News